Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Xiaoyan Wang"'
Autor:
Zhiyan Hu, Ting Long, Yidan Ma, Jiaxian Zhu, Lingfang Gao, Yan Zhong, Xia Wang, Xiaoyan Wang, Zuguo Li
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 39, Iss 1, Pp 1-15 (2020)
Abstract Background GLYR1 has a high mutation frequency in microsatellite instability colorectal cancer (MSI CRC) and is presumed to be a novel tumor suppressor. However, the role of GLYR1 in tumors has never been studied. In particular, the downregu
Externí odkaz:
https://doaj.org/article/3bbf5b48da674c22b7ee20fcbe448c40
Autor:
Zhixin Ling, Xiaoyan Wang, Tao Tao, Lei Zhang, Han Guan, Zonghao You, Kai Lu, Guangyuan Zhang, Shuqiu Chen, Jianping Wu, Jinke Qian, Hui Liu, Bin Xu, Ming Chen
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 36, Iss 1, Pp 1-15 (2017)
Abstract Background Though androgen deprivation therapy is the standard treatment for prostate cancer (PCa), most patients would inevitably progress to castration-resistant prostate cancer (CRPC) which is the main cause of PCa death. Therefore, the i
Externí odkaz:
https://doaj.org/article/d27c19d762334feca82dfa4fc480bf45
Autor:
Zhiyan Hu, Ting Long, Yidan Ma, Jiaxian Zhu, Lingfang Gao, Yan Zhong, Xia Wang, Xiaoyan Wang, Zuguo Li
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 39, Iss 1, Pp 1-1 (2020)
An amendment to this paper has been published and can be accessed via the original article.
Externí odkaz:
https://doaj.org/article/0c7a53da59f44284a150bf237cb52534
Autor:
Jianping Wu, Zhixin Ling, Guangyuan Zhang, Zonghao You, Han Guan, Ming Chen, Kai Lu, Jinke Qian, Tao Tao, Shuqiu Chen, Lei Zhang, Bin Xu, Xiaoyan Wang, Hui Liu
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 36, Iss 1, Pp 1-15 (2017)
Journal of Experimental & Clinical Cancer Research : CR
Journal of Experimental & Clinical Cancer Research : CR
Background Though androgen deprivation therapy is the standard treatment for prostate cancer (PCa), most patients would inevitably progress to castration-resistant prostate cancer (CRPC) which is the main cause of PCa death. Therefore, the identifica